BMO Capital initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $50 price target The gene therapy company has “two major differences from the typical gene therapy stories,” namely that Rocket’s liver-targeted gene therapies “likely” offer a life-long effect as they target the heart and the company’s programs target diseases with limited or no treatment options and severe unmet need. The company’s main program targets Danon Disease, a severe cardiomyopathy that causes early death and has no approved treatment, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals price target raised to $52 from $51 at Scotiabank
- Rocket Pharmaceuticals price target lowered to $36 from $39 at Canaccord
- Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
- Rocket Pharmaceuticals Advances Gene Therapy Pipeline
- Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
Questions or Comments about the article? Write to editor@tipranks.com